$BLUE
bluebird bio, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019003694 Filed on February 21, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018 Q3
Revenue $12.47M $19.24M $11.53M
YoY Change -21.85% 361.68% 49.5%
Cost Of Revenue $430.0K $800.0K $29.00K
YoY Change 2429.41% -97.36%
Gross Profit $12.04M $18.40M $11.50M
YoY Change -24.46% 338.1% 73.94%
Gross Profit Margin 96.55% 95.62% 99.75%
Selling, General & Admin $60.28M $53.50M $44.50M
YoY Change 72.72% 83.85% 93.48%
% of Gross Profit 500.61% 290.76% 386.99%
Research & Development $122.6M $119.7M $116.7M
YoY Change 26.3% 29.27% 89.69%
% of Gross Profit 1018.52% 650.54% 1015.25%
Depreciation & Amortization $3.780M $4.550M $4.410M
YoY Change -5.97% 25.0% 21.82%
% of Gross Profit 31.39% 24.73% 38.35%
Operating Expenses $182.9M $176.2M $161.3M
YoY Change 37.96% 45.7% 89.0%
Operating Profit -$171.2M -$157.0M -$149.8M
YoY Change 46.77% 34.42% 92.92%
Interest Expense $10.10M $4.000M $4.591M
YoY Change 627.81% 700.0% -497.49%
% of Operating Profit
Other Income/Expense, Net -$3.389M $1.900M -$252.0K
YoY Change -3046.96% -2000.0% -3250.0%
Pretax Income -$164.5M -$148.8M -$145.5M
YoY Change 42.85% 27.18% 84.61%
Income Tax -$15.00K $200.0K
% Of Pretax Income
Net Earnings -$164.4M -$149.0M -$145.5M
YoY Change 42.84% 27.12% 84.61%
Net Earnings / Revenue -1318.63% -774.43% -1261.97%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.989M -$2.724M -$2.730M
COMMON SHARES
Basic Shares Outstanding 54.95M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.731B $1.891B $1.675B
YoY Change 54.31% 46.61% 129.87%
Cash & Equivalents $221.7M $402.6M $952.1M
Short-Term Investments $1.509B $1.489B $723.1M
Other Short-Term Assets $39.40M $33.70M $30.00M
YoY Change -7.29% 13.85% 10.29%
Inventory
Prepaid Expenses $19.76M $24.13M
Receivables $3.800M
Other Receivables $0.00
Total Short-Term Assets $1.365B $1.419B $1.725B
YoY Change 17.26% 7.27% 127.41%
LONG-TERM ASSETS
Property, Plant & Equipment $298.6M $246.6M $232.9M
YoY Change 46.23% 23.55% 27.67%
Goodwill $13.13M $13.13M
YoY Change 0.0%
Intangibles $13.17M $14.11M
YoY Change -22.22%
Long-Term Investments $408.9M $506.1M $323.8M
YoY Change -8.07% 56.11% -21.77%
Other Assets $40.60M $44.81M $42.57M
YoY Change 65.04% 87.16% 114.99%
Total Long-Term Assets $773.6M $823.8M $626.4M
YoY Change 10.09% 42.58% -3.19%
TOTAL ASSETS
Total Short-Term Assets $1.365B $1.419B $1.725B
Total Long-Term Assets $773.6M $823.8M $626.4M
Total Assets $2.139B $2.243B $2.352B
YoY Change 14.56% 18.01% 67.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $30.20M $17.83M $12.89M
YoY Change 151.67% 38.51% 4.8%
Accrued Expenses $63.00M $96.70M $86.40M
YoY Change 4.83% 75.18% 109.2%
Deferred Revenue $11.49M $18.60M $22.58M
YoY Change -74.66% -27.55%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.400M $1.300M
YoY Change -100.0% 27.27% 62.5%
Total Short-Term Liabilities $146.7M $146.4M $131.6M
YoY Change 36.09% 53.15% 71.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $153.3M $153.7M
YoY Change -100.0% -0.9% -0.32%
Other Long-Term Liabilities $219.8M $3.107M $2.634M
YoY Change 540.82% 11.76% -92.11%
Total Long-Term Liabilities $219.8M $3.107M $2.634M
YoY Change 16.42% 11.76% -98.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $146.7M $146.4M $131.6M
Total Long-Term Liabilities $219.8M $3.107M $2.634M
Total Liabilities $366.5M $357.8M $351.0M
YoY Change 23.57% 29.1% 32.75%
SHAREHOLDERS EQUITY
Retained Earnings -$1.499B -$1.350B
YoY Change 64.02%
Common Stock $547.0K $547.0K
YoY Change 10.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.772B $1.885B $2.001B
YoY Change
Total Liabilities & Shareholders Equity $2.139B $2.243B $2.352B
YoY Change 14.56% 18.01% 67.29%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$164.4M -$149.0M -$145.5M
YoY Change 42.84% 27.12% 84.61%
Depreciation, Depletion And Amortization $3.780M $4.550M $4.410M
YoY Change -5.97% 25.0% 21.82%
Cash From Operating Activities -$154.2M -$129.7M -$74.48M
YoY Change 41.66% 36.01% 32.22%
INVESTING ACTIVITIES
Capital Expenditures $19.32M -$12.90M -$22.15M
YoY Change 159.27% -31.49% 467.95%
Acquisitions
YoY Change
Other Investing Activities -$17.59M -$408.2M $56.02M
YoY Change -93.16% -979.36% -114.19%
Cash From Investing Activities -$36.91M -$421.1M $33.87M
YoY Change -86.06% -1626.28% -108.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $10.22M 1.920M 658.8M
YoY Change -85.74% -99.67% 10664.54%
NET CHANGE
Cash From Operating Activities -$154.2M -129.7M -74.48M
Cash From Investing Activities -$36.91M -421.1M 33.87M
Cash From Financing Activities $10.22M 1.920M 658.8M
Net Change In Cash -$180.8M -548.9M 618.2M
YoY Change -40.09% -205.45% -237.68%
FREE CASH FLOW
Cash From Operating Activities -$154.2M -$129.7M -$74.48M
Capital Expenditures $19.32M -$12.90M -$22.15M
Free Cash Flow -$173.5M -$116.8M -$52.33M
YoY Change 49.2% 52.62% -0.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
885000
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54951177
CY2018Q2 dei Entity Public Float
EntityPublicFloat
7882817517
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
402579000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
758505000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
982725000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
531604000
CY2018Q4 blue Tenant Improvement Costs Reimbursable Current
TenantImprovementCostsReimbursableCurrent
19000
CY2017Q4 blue Tenant Improvement Costs Reimbursable Current
TenantImprovementCostsReimbursableCurrent
3112000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
19762000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
21171000
CY2018Q4 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
13912000
CY2017Q4 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
8377000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1418997000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
1322769000
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
506123000
CY2017Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
324193000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
246622000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
199606000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13169000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16931000
CY2018Q4 us-gaap Goodwill
Goodwill
13128000
CY2017Q4 us-gaap Goodwill
Goodwill
13128000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44805000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23940000
CY2018Q4 us-gaap Assets
Assets
2242844000
CY2017Q4 us-gaap Assets
Assets
1900567000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17831000
CY2018 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-267830000
CY2017 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
CY2016 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
CY2018 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2999000
CY2016 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4091000
CY2017 us-gaap Operating Expenses
OperatingExpenses
367592000
CY2016 us-gaap Operating Expenses
OperatingExpenses
273985000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
57065000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12873000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
99393000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18602000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
25674000
CY2018Q4 blue Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
10605000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
146431000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
95612000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16338000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21763000
CY2018Q4 blue Collaboration Research Advancement Non Current
CollaborationResearchAdvancementNonCurrent
33349000
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5230000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2231000
CY2018Q4 blue Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
153319000
CY2017Q4 blue Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
154749000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3107000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2780000
CY2018Q4 us-gaap Liabilities
Liabilities
357774000
CY2017Q4 us-gaap Liabilities
Liabilities
277135000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
547000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
494000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3386958000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2540951000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3627000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4205000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1498808000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-913808000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1885070000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1623432000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2242844000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1900567000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54738000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49406000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54738000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49406000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
174129000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3782000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1267000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1527000
CY2017 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-525000
CY2018 us-gaap Operating Expenses
OperatingExpenses
626602000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-572023000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-332165000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2001000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-71000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-264119000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
210000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-612000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-263507000
CY2018 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
578000
CY2017 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
-3056000
CY2016 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
1142000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
578000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3056000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1142000
CY2018 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
400000
CY2017 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0
CY2016 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
600000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
850496000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
234731000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6145000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
677000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39756000
CY2016 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1142000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
869440000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1006570000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31686000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1153000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
53282000
CY2017 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustments During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentsDuringPeriodNetOfTax
-3056000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
649368000
CY2018 blue Stock Issued During Period Value In Connection With Collaborative Arrangement
StockIssuedDuringPeriodValueInConnectionWithCollaborativeArrangement
54484000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29768000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1604000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
110836000
CY2018 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustments During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentsDuringPeriodNetOfTax
578000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-262365000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
34588000
CY2018 us-gaap Profit Loss
ProfitLoss
-555625000
CY2017 us-gaap Profit Loss
ProfitLoss
-335643000
CY2016 us-gaap Profit Loss
ProfitLoss
-263507000
CY2018 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2999000
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
15269000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
53487000
CY2017 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
-2189000
CY2016 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2675000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17158000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
13538000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9648000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
110836000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
53282000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
39756000
CY2018 us-gaap Available For Sale Equity Securities Gross Unrealized Gain
AvailableForSaleEquitySecuritiesGrossUnrealizedGain
2154000
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5880000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3153000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2825000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24288000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20092000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14318000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3614000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
526000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6658000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
37832000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5848000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
22051000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-41872000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1024000
CY2016 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4565000
CY2018 blue Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
-43954000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-413426000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-280553000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-189647000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55737000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
62242000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28029000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1517982000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
686204000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
348225000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
894284000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
431816000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
443364000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-679435000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-316630000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67110000
CY2017 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1074000
CY2016 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2025000
CY2018 blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
3098000
CY2017 blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
38021000
CY2016 blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
1663000
CY2018 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1017000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
574000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
649368000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1006570000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
234962000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31759000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33231000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6934000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
737692000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1076174000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
241534000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-355169000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
478991000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
118997000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772268000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293277000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
174280000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417099000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
15494000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
11411000
CY2017 blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
3271000
CY2016 blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
48034000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7449000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2566000
CY2018 blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
14000
CY2017 blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
3112000
CY2016 blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
8542000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s clinical programs in severe genetic diseases include its LentiGlobin<sup style="font-size:85%; vertical-align:top">&#174;</sup> product candidate to treat transfusion-dependent &#946;-thalassemia, or TDT, and to treat sickle cell disease, or SCD, and its Lenti-D<sup style="font-size:85%; vertical-align:top">TM</sup> product candidate to treat cerebral adrenoleukodystrophy, or CALD, a rare hereditary neurological disorder. In the second half of 2018, the Company filed a marketing authorization application with the EMA for the LentiGlobin product candidate for the treatment of adult and adolescent patients with TDT and non-<font style="font-size:12pt;"> </font>&#946;<sup style="font-size:85%; vertical-align:top">0</sup>/&#946;<sup style="font-size:85%; vertical-align:top">0</sup> genotypes. If the application is approved, the Company expects to begin commercializing and generating product revenues in the second half of 2019. The Company&#8217;s programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121 and bb21217, which are product candidates in oncology under the Company&#8217;s collaboration arrangement with Celgene Corporation (&#8220;Celgene&#8221;), are CAR T cell product candidates for the treatment of multiple myeloma. Refer to Note 10, &#8220;<font style="font-style:italic;">Collaborative arrangements</font>&#8221; for further discussion of the Company&#8217;s collaboration with Celgene.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018, the Company had cash, cash equivalents and marketable securities of $1.9 billion. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund current planned operations for at least the next twelve months. </p>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and judgments are used in the following areas, among others: fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, financing lease obligations, contingent consideration, stock-based compensation expense, accrued expenses, and income taxes.&nbsp;&nbsp;In addition, estimates and judgments are used in the Company&#8217;s accounting for its revenue-generating arrangements, in particular as it relates to determining the standalone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, and the period of performance over which revenue may be recognized.</p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of credit risk and off-balance sheet risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s marketable securities primarily consist of U.S. Treasury securities, U.S. government agency securities and certificates of deposit, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure. </p>
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15849000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13400000
CY2018 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1992-04-16
CY2018Q4 us-gaap Investments And Cash
InvestmentsAndCash
1900000000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
30100000
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
9500000
CY2016 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3800000
CY2018 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
15500000
CY2017 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
11400000
CY2016 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
CY2018Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
45344000
CY2018Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31468000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-943183000
CY2018 us-gaap Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment
ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
Under ASC 605, the Company accounted for contract modifications to the Celgene collaboration as they occurred and the accounting for those changes was prospective in nature. Through the application of the practical expedient discussed above in connection with the adoption of Topic 606, the Company reflected the aggregate effect of all modifications to the Celgene collaboration when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price. As a result, although the performance obligations identified under Topic 606 were generally consistent with the units of account identified under ASC 605, the timing of the allocation of the transaction price to the identified performance obligations under Topic 606 differed from the allocations of consideration under ASC 605. Accordingly, the transaction price ultimately allocated to each performance obligation under Topic 606 differed from the amounts allocated under ASC 605.
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
278887000
CY2018Q4 blue Restricted Cash Included In Receivables And Other Current Assets
RestrictedCashIncludedInReceivablesAndOtherCurrentAssets
364000
CY2016Q4 blue Restricted Cash Included In Receivables And Other Current Assets
RestrictedCashIncludedInReceivablesAndOtherCurrentAssets
627000
CY2018Q4 blue Restricted Cash Included In Restricted Cash And Other Non Current Assets
RestrictedCashIncludedInRestrictedCashAndOtherNonCurrentAssets
14156000
CY2017Q4 blue Restricted Cash Included In Restricted Cash And Other Non Current Assets
RestrictedCashIncludedInRestrictedCashAndOtherNonCurrentAssets
13763000
CY2016Q4 blue Restricted Cash Included In Restricted Cash And Other Non Current Assets
RestrictedCashIncludedInRestrictedCashAndOtherNonCurrentAssets
13763000
CY2018Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
20017000
CY2018Q4 blue Equity Securities Unrealized Gain
EquitySecuritiesUnrealizedGain
2150000
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
22167000
CY2018Q4 blue Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
1488746000
CY2017Q4 blue Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
859375000
CY2018Q4 blue Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
3113000
CY2017Q4 blue Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
1000
CY2018Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2018Q4 blue Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
3011000
CY2017Q4 blue Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
3579000
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
1488848000
CY2017Q4 us-gaap Marketable Securities
MarketableSecurities
855797000
CY2018 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
90 days or less
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
787500000
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
704100000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
315300000
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
134400000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9800000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5900000
CY2017Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
14520000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
13763000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
275798000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
215455000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29176000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28567000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19657000
CY2018Q4 blue Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
21618000
CY2017Q4 blue Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
8480000
CY2018Q4 blue Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
11891000
CY2017Q4 blue Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
8082000
CY2018Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
7739000
CY2017Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
4584000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1830000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1402000
CY2018Q4 blue Other Accrued Goods And Services Current
OtherAccruedGoodsAndServicesCurrent
25051000
CY2017Q4 blue Other Accrued Goods And Services Current
OtherAccruedGoodsAndServicesCurrent
12971000
CY2018Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1424000
CY2017Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1051000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1273000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
838000
CY2016Q4 blue Contractual Obligation Agreement Period
ContractualObligationAgreementPeriod
P5Y
CY2016Q4 blue Contractual Obligation Agreement Renewal Period
ContractualObligationAgreementRenewalPeriod
P3Y
CY2016Q4 blue Contractual Obligation Fees
ContractualObligationFees
3000000
CY2016Q4 blue Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
2000000
CY2018Q3 blue Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
1000000
CY2018 blue Contractual Obligation Termination Description
ContractualObligationTerminationDescription
The Company may terminate this agreement with twelve months’ notice and a one-time termination fee.
CY2018Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
36485000
CY2018Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
38033000
CY2018Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
38420000
CY2018Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
33319000
CY2018Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
33721000
CY2018Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
97864000
CY2018Q4 us-gaap Contractual Obligation
ContractualObligation
277842000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
9800000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
9000000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8300000
CY2018Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
69827000
CY2018Q4 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
74529000
CY2018Q4 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
14358000
CY2018Q4 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
24311000
CY2018Q4 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
25040000
CY2018Q4 blue Purchase Obligation Due In Sixth Year And Thereafter
PurchaseObligationDueInSixthYearAndThereafter
25792000
CY2018Q4 us-gaap Purchase Obligation
PurchaseObligation
233857000
CY2018 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stock are entitled to one vote per share
CY2018Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3900000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4400000
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3200000
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
300000
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3300000
CY2018Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
400000
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
436800000
CY2017Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
569800000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
48700000
CY2016Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
234700000
CY2018Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
100000000
CY2017Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
105.00
CY2017Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
185.00
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
185.00
CY2016Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
76.00
CY2018Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
238.10
CY2018Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
162.50
CY2018Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
600600000
CY2018Q3 blue Common Stock Amount Attributable To Prepayment Of Joint Research Activities
CommonStockAmountAttributableToPrepaymentOfJointResearchActivities
45500000
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7204000
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5970000
CY2018 blue Deferred Revenue Released
DeferredRevenueReleased
41900000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
2000000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1500000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
110836000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53282000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39756000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.755
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.781
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3755000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1602000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
575000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
139000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4643000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2200000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4641000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
67.91
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
185.45
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
51.82
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
130.93
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
108.56
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
64.80
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
108.53
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
110812000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
90785000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
110593000
CY2017Q4 blue Deferred Tax Assets Stock Based Compensation
DeferredTaxAssetsStockBasedCompensation
19519000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
8886000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
125.12
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
62.03
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.22
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
73100000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15300000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-440473000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-266236000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-210188000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-114965000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-69197000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-53931000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
324000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
115000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
222000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
95000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-307000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-588000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-52000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-24000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.033
CY2018 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.009
CY2017 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.027
CY2016 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.053
CY2018 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.065
CY2017 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.128
CY2016 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.150
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.044
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.069
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.070
CY2018 blue Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0.001
CY2017 blue Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
-0.316
CY2016 blue Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.291
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.146
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.399
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
298701000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
194160000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
167517000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
131289000
CY2018Q4 blue Deferred Tax Assets Capitalized License Fee And Research And Development Expenses
DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses
18083000
CY2017Q4 blue Deferred Tax Assets Capitalized License Fee And Research And Development Expenses
DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses
13629000
CY2018Q4 blue Deferred Tax Assets Capital Lease
DeferredTaxAssetsCapitalLease
42059000
CY2017Q4 blue Deferred Tax Assets Capital Lease
DeferredTaxAssetsCapitalLease
42025000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
21442000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12795000
CY2018Q4 blue Deferred Tax Assets Stock Based Compensation
DeferredTaxAssetsStockBasedCompensation
31858000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
6262000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
588546000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
419679000
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3579000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
4567000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
41472000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
42062000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
543495000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
373050000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
170400000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3370000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
8725000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
12095000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5584000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4241000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4009000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15957000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7851000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11528000
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19243000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
132586000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
156465000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
161347000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
176204000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-116629000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-148614000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-149819000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-156961000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-115126000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-145996000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-145480000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-149023000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.31
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.91
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.73
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.72
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6832000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16716000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7711000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4168000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
76745000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
84538000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
85369000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
120940000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-69913000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-67822000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77658000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-116772000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-68712000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-70898000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-78805000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-117228000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52

Files In Submission

Name View Source Status
0001564590-19-003694-index-headers.html Edgar Link pending
0001564590-19-003694-index.html Edgar Link pending
0001564590-19-003694.txt Edgar Link pending
0001564590-19-003694-xbrl.zip Edgar Link pending
blue-10k_20181231.htm Edgar Link pending
blue-20181231.xml Edgar Link completed
blue-20181231.xsd Edgar Link pending
blue-20181231_cal.xml Edgar Link unprocessable
blue-20181231_def.xml Edgar Link unprocessable
blue-20181231_lab.xml Edgar Link unprocessable
blue-20181231_pre.xml Edgar Link unprocessable
blue-ex1023_788.htm Edgar Link pending
blue-ex1024_789.htm Edgar Link pending
blue-ex1025_790.htm Edgar Link pending
blue-ex211_6.htm Edgar Link pending
blue-ex231_7.htm Edgar Link pending
blue-ex311_11.htm Edgar Link pending
blue-ex312_8.htm Edgar Link pending
blue-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g1glmn4imv1u000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending